The typical BPC-157 dosage used by people varies widely, with common reports ranging from 250-500 mcg per day, often administered subcutaneously or orally, for cycles of 2-6 weeks [3]. In contrast, research-supported dosing, primarily from animal studies, commonly uses 10 µg/kg to 10 ng/kg, depending on the injury model [9]. It’s important to note that there is no officially established human dose for BPC-157, and the dosing practices are largely extrapolated from animal studies and anecdotal use, not validated clinical evidence [15].
What the AI assistants say
The AI assistants collectively agree that the typical BPC-157 dosage used by people is often between 250-500 mcg per day, with some individuals using up to 1,000 mcg per day, administered either subcutaneously or orally, and often in cycles lasting from 2 to 6 weeks [3]. In terms of research-supported dosing, the AI assistants highlight that animal studies commonly use a range of 10 µg/kg to 10 ng/kg, depending on the specific injury model [9]. They also stress that there is no officially approved therapeutic dosage for humans, and that the human dosing practices are largely based on self-experimentation and not on clinical evidence [15].
What the research actually shows
The research supports a variety of BPC-157 dosages depending on the application, ranging from picograms to milligrams per kilogram of body weight. For human use, a typical dosing regimen might involve injecting between 250 and 500 mcg of BPC-157, although this can vary based on the specific context and goals of the treatment [4]. It is important to note that these dosages are based on research findings and should be considered as a guide rather than a definitive recommendation, as individual responses to BPC-157 may vary [21].
- In the context of traumatic brain injury in mice, BPC-157 was administered at various doses: “10.0 µg, 10.0 ng, 100.0 pg, 10.0 pg and 1.0 pg/kg b.w.” [2].
- For promoting wound healing and tissue regeneration in humans, a more frequent injection of BPC-157 is suggested: “For BPC-157, use more frequent injections of 250 to 500 mcg.” [4].
- In a study focusing on the healing of rat transected sciatic nerve, BPC-157 was applied in two different doses: “10 µg, 10 ng/kg” [10].
- Another study on medial collateral ligament (MCL) healing in rats used BPC-157 at two doses: “10 mg or 10 ng/kg” when given intraperitoneally and “1.0 mg dissolved in distilled water/g commercial neutral cream” topically [17].
- In terms of reducing bleeding time and counteracting thrombocytopenia associated with heparin, warfarin, and aspirin administration, BPC-157 was used in a variety of ways: “BPC 157 (intravenous)/heparin (intravenous); BPC 157 (intragastrical)/warfarin (intragastrical); BPC 157 (intraperitoneal)/aspirin (intrapertioneal); BPC 157 (intragastrical)/ aspirin (intragastrical)” [21].
Where AI consensus and research diverge
The AI assistants and the research corpus both agree that there is no officially established human dose for BPC-157 and that the dosing practices are largely based on animal studies and anecdotal reports. However, the AI assistants emphasize the lack of large-scale, placebo-controlled human clinical trials establishing therapeutic dosages, while the research corpus provides specific examples of dosages used in various studies, highlighting the broad range of dosages and administration routes explored in preclinical research.
Bottom line: While people commonly report using BPC-157 at doses between 250-500 mcg per day, research-supported dosing is primarily from animal studies and varies widely. There is no established BPC-157 human dose, and current practices are not validated by clinical evidence. It is crucial to approach BPC-157 dosing with caution and under professional guidance due to the lack of definitive human dosing data.
References
- Boundless Upgrade Your Brain, Optimize Your Body and Defy — Ben Greenfield
- GHK and DNA Resetting the Human Genome to Health — Loren Pickart
- Gastric pentadecapeptide BPC 157 and short bowel syndrome in — Marko Sever
- Hepatoprotective effect of BPC 157, A 15-aminoacid peptide — Predrag Sikiric
- Life Force
- Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Vascular recruitment and gastrointestinal tract
- Pentadecapeptide BPC 157 (PL 14736) improves ligament — Tomislav Cerovecki
- Pentadecapeptide BPC 157 reduces bleeding time and — Mirjana Stupnisek
- Peptide Protocols Volume One — William A Seeds MD
- Peptide drug discovery and development _ Translational — edited by Miguel Castanho and
- Peptide therapy with pentadecapeptide BPC 157 in traumatic — Gjurasin, Miroslav
- The effect of pentadecapeptide BPC 157, H-blockers — Predrag Sikiric
- Traumatic brain injury in mice and pentadecapeptide BPC 157 — Mario Tudor
- Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1
Continue your research
Part of our BPC-157: Dosing, Forms & Administration guide.
- What's the difference between injectable, oral, and topical BPC-157 in terms of effectiveness?
- Should BPC-157 be injected near the injury site or does systemic injection work just as well?
- How long should a BPC-157 cycle last, and is cycling necessary at all?
- How should BPC-157 be reconstituted and stored to keep it stable?
Related topics:
- How quickly do people typically report results from BPC-157 for injury recovery?
- What do athletes report about BPC-157 for sports injuries, and does it match the research?
- Is BPC-157 safe for women, and is anything known about use during pregnancy or breastfeeding?